NSEAction(s) initiated or orders passed24 Oct 2026 · 24 Oct 2026, 12:17 pm
Action(s) initiated or orders passed
Sahajanand Medical Technologies Limited · SMT
✦ AI SummaryRegulatory
Sahajanand Medical Technologies Limited has received a summons under Section 70 of the Central Goods and Services Tax Act, 2017, for verification of books of accounts. The company is cooperating with the authorities and does not expect any material financial impact.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern3/10
Regulatory Risk8/10
Balance Sheet Risk2/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Sahajanand Medical Technologies Limited has informed the Exchange about summons received under section 70 of Central Goods and Service tax Act.
Attachments (1)
📄pdf
Download →
SAHAJANAND_24102026121647_Disclosure_Under_Reg_30_Summons_under_GST_ACT.pdf
View document text
Ref: 05/SE/LC/2026-27
Date: October 24, 2026
To, To,
National Stock Exchange of India Limited BSE Limited (“BSE”)
(“NSE”) Listing Department
Listing Department Corporate Relationship Department
Exchange Plaza, C-1 Block G, Bandra Kurla Phiroze Jeejeebhoy Towers,
Complex Bandra (East), Mumbai – 400051 Dalal Street, Fort, Mumbai - 400 001
NSE Scrip Symbol: SMT BSE Scrip Code: 545001
ISIN: INE356Y01018 ISIN: INE356Y01018
Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015 (“SEBI Listing Regulations”)
Ref. No: DIN 202610DWW0000018FC61 dated 16th October 2026 (received on 23rd October 2026)
issued to GSTIN 27AAFCS7694L1ZI
Dear Sir/Madam,
Pursuant to Regulation 30 of SEBI Listing Regulations, we hereby inform that the Company has
received a Summons dated October 16,2026 (received on 23rd October 2026) issued under Section 70
of the Central Goods and Services Tax Act, 2017 by the Superintendent/ Appraiser/ Senior Intelligence
Officer of DGGI, Mumbai Zonal Unit, Mumbai.
The Summons has been issued to our GSTIN 27AAFCS7694L1ZI in connection with an initiation of
inquiry under the Central Goods and Services Tax Act, 2017.
At this stage, the Company is fully cooperating with the authorities and will provide all necessary
information as required. This Summons does not have any material financial impact on the Company.
The Company will keep the Stock Exchange(s) informed of further significant developments, if any.
Details required as per SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November,
2024, as amended from time to time, are enclosed as Annexure A to this disclosure.
We request you to take the afore-mentioned information on record and oblige.
This is for your information and records.
Thanking you,
For Sahajanand Medical Technologies Limited
Bhargav Dhirajlal Kotadia
Managing Director & Chief Executive Officer
DIN: 06575042
Annexure A
Sl. Particulars Information Remarks
1 Name of the Authority Superintendent/ Appraiser/ Senior Intelligence
Officer of DGGI Branch,
Zonal Unit Mumbai, NTC House, 1st floor,
Ballard Estate, Fort, Mumbai - 400001
2 Nature and details of the action initiated Summons issued under Section 70 of the
or order passed Central Goods and Services Tax Act, 2017, for
verification of books of accounts.
3 Date of receipt of notice, direction or Summons dated 16 October 2026 received on
order, including any ad-interim or October 23, 2026
interim orders, or any other
communication from the authority
4 Details of the The Summons does not specify violations. It
violation(s)/contravention(s) committed states to give evidence in relation to GST
or alleged to be committed compliance for re-imbursements made to
foreign subsidiaries for clinical trials
5 Impact on financial, operation or other No material financial, operational, or business
activities of the listed entity, quantifiable impact at this stage. The Company is fully
in monetary terms to the extent possible. cooperating with the authorities and will
provide necessary information